The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has approved Nuvaxovid, the COVID-19 vaccine developed by Novavax, for 12 to 17 year old children.
This approval follows a review of the safety, effectiveness, and quality of the COVID-19 vaccine in the particular age group, and the expert advice from the independent scientific advisory body, known as Commission on Human Medicines, of the UK government.
Dr. June Raine, chief executive of MHRA, said that following their review of the quality, safety, and effectiveness of Nuvaxovid in 12 to 17 year olds, and he is pleased to confirm that the vaccine has now been authorized in the age group. He also said that in reaching the decision, they had taken advice from the Commission on Human Medicines of the UK government.
The Conditional Marketing Authorisation (CMA) extension, which is granted by the UK MHRA is valid in Great Britain only, and was also approved through the decision reliance route of European Commission.
The COVID-19 vaccine by Novavax is authorised for children aged 12 to 17 years in Northern Ireland under the CMA extension, which was granted by the European Medicines Agency on July 1, 2022.
Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.
I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.
I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!
